Welcome to our dedicated page for Adaptin Bio SEC filings (Ticker: APTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Adaptin Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Adaptin Bio's regulatory disclosures and financial reporting.
Adaptin Bio, Inc. files a prospectus supplement updating its S-1 to register resale of 1,901,482 shares of common stock and notes 2,233,083 shares underlying warrants held by selling stockholders. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026, its Form 10-K for fiscal 2025 and an 8-K.
The Company reported $301,309 in cash as of March 31, 2026, a net loss of $1,146,096 for Q1 2026 and an accumulated deficit of $10,437,897. Shares outstanding were stated as 8,851,229 as of May 14, 2026. The supplement updates offering and disclosure materials and should be read with the underlying Prospectus.
Adaptin Bio, Inc. reported a Q1 2026 net loss of $1,146,096, wider than the prior-year loss of $603,084, as it increased investment in R&D and public-company overhead.
The company ended March 31, 2026 with cash and equivalents of $301,309 and an accumulated deficit of $10,437,897. Management disclosed that these conditions raise substantial doubt about its ability to continue as a going concern and expects to rely on additional equity or debt financings. During the quarter, Adaptin raised gross proceeds of $652,000 through its Follow-on Offering, issued 130,400 new shares, and continued advancing its APTN-101 brain cancer program while operating with a working capital deficit.
Adaptin Bio, Inc. reported that its common shares have been approved for quotation on the OTCQB Venture Market under the ticker symbol APTN. The company expects trading to begin in approximately 6–8 weeks and plans to share any material updates as they occur.
Adaptin is a biotechnology company developing precision cancer therapeutics focused on hard-to-reach tissues, including the brain. Its lead candidate, APTN-101, a brain bispecific T cell engager built on the BRiTE delivery platform, is FDA-cleared for a Phase 1 clinical trial in glioblastoma and has shown anti-tumor activity and a favorable safety profile in multiple preclinical models.
Adaptin Bio, Inc. is an early-stage biopharmaceutical company developing its BRiTE platform to deliver therapeutics across the blood-brain barrier, with lead candidate APTN-101 targeting EGFRvIII-positive glioblastoma and other cancers. The company completed a merger with Unite Acquisition 1 Corp. in February 2025, becoming a public entity.
For the year ended December 31, 2025, Adaptin reported a net loss of $5.17 million and an accumulated deficit of $9.29 million. Cash and cash equivalents were $459,174, leading management to state substantial doubt about its ability to fund operations for the next twelve months without new capital. Operations are funded primarily through private placements and prior bridge notes that converted into equity.
The company holds an exclusive license from Duke University covering its BRiTE technology, owes clinical and commercial milestones totaling up to $11.7 million plus royalties, and relies on contract manufacturers and sponsored research at Duke. As of March 26, 2026, Adaptin had 8,786,229 common shares outstanding and an approximate non-affiliate equity market value of $9.3 million, with no active trading market for its stock.